IMPORTANT SAFETY
INFORMATION
Warnings and Precautions for Risk of Low Blood
Pressure
Transient decreases in blood pressure were observed in
clinical
studies. Patients with
significant cardiac or vascular disease and patients on
anti-hypertensive medicinal products
were excluded from participation in VOXZOGO clinical trials.
To
reduce the risk of a decrease
in blood pressure and associated symptoms (dizziness,
fatigue,
and/or nausea), patients should
be well hydrated, have adequate food intake, and drink
approximately
8-10 ounces of fluid in
the hour prior to VOXZOGO administration.
In a 52-week, randomized, double-blind, placebo-controlled
trial
in
121 subjects with
achondroplasia, subjects aged from 5.1 to 14.9 years, (Study
1)
eight (13%) of 60 patients
treated with VOXZOGO had a total of 11 events of transient
decrease
in blood pressure,
compared to 3 (5%) of 61 patients on placebo, over a 52-week
treatment period. The median time
to onset from injection was 31 (18 to 120) minutes, with
resolution
within 31 (5 to 90)
minutes in VOXZOGO-treated subjects. Two out of 60 (3%)
VOXZOGO-treated patients each had one
symptomatic episode of decreased blood pressure with
vomiting
and/or
dizziness compared to 0
of 61 (0%) patients on placebo.
Adverse Reactions:
Adverse reactions that occurred in ≥5% of patients treated
with
VOXZOGO and at a rate greater
than that of placebo in the phase 3 study are injection site
reactions (including erythema,
swelling, urticaria, pain, bruising, pruritus, hemorrhage,
discoloration, and induration),
vomiting, arthralgia, decrease in blood pressure,
gastroenteritis,
diarrhea, dizziness, ear
pain, influenza, fatigue, seasonal allergy, and dry skin.
VOXZOGO-treated patients had an
increase in alkaline phosphatase levels (17%), and was noted
as
a
laboratory abnormality.
Injection site reactions: In Study 1, injection site
reactions occurred in 51 (85%)
subjects receiving VOXZOGO and 50 (82%) subjects receiving
placebo
over a 52-week period of
treatment. Patients receiving VOXZOGO experienced a total of
6983
events of injection site
reactions, while patients receiving placebo experienced a
total
of
1776 events of injection
site reactions, over a 52-week period, representing 120.4
events
per
patient/year exposure and
29.2 events per patient/year exposure, respectively. Two
patients in
the VOXZOGO arm
discontinued treatment due to adverse events of pain and
anxiety
with injections.
Pediatric Patients 0 to <5 Years:
The safety of VOXZOGO in pediatric patients 0 to <5 years
with
achondroplasia was evaluated
in a 52-week randomized, double-blind, placebo-controlled
study
(Study 2). In this study, 64
patients from birth to <5 years of age were randomized to
receive
either a daily vosoritide
dose with similar exposure to that characterized to be safe
and
effective in children with ACH
aged ≥5 years old, or placebo. An additional 11 patients
received
open-label treatment as part
of this study. The most common adverse reactions (>10%)
reported
in pediatric patients 0 to
<5 years were injection site reactions (86%) and rash
(28%).
The
overall safety profile of
VOXZOGO in pediatric patients 0 to <5 years was similar
to
that
seen in older pediatric
patients.
Administration and Monitoring:
VOXZOGO is administered as a daily subcutaneous injection.
Prior
to
use, instruct caregivers
on proper preparation and administration of VOXZOGO, and
ensure
caregivers have demonstrated
the ability to perform a subcutaneous injection.
Monitor and assess patient body weight, growth, and physical
development regularly every 3-6
months. Adjust dosage according to the patient’s actual body
weight.
Permanently discontinue
treatment with VOXZOGO upon confirmation of no further
growth
potential, indicated by closure
of epiphyses.
Special Populations:
- There are no available data on the use of VOXZOGO in
pregnant
women, or data on the
presence of VOXZOGO in human milk, the effects on the
breastfed
infant, or the effects on
milk production.
- The influence of renal impairment on the
pharmacokinetics of
VOXZOGO has not been
evaluated. No dosage adjustment is needed for patients
with
eGFR
≥60 mL/min/1.73
m2. VOXZOGO is not recommended for patients
with
eGFR
<60 mL/min/1.73
m2.
You may report side effects to the FDA at
1-800-FDA-1088
or www.fda.gov/medwatch.
You may also report side
effects to BioMarin at 1-866-906-6100.
Please see additional safety information in the full
Prescribing Information.